Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies.
Location: Dominican Republic, Distrito Nacional, Santo Domingo
Employees: 1001-5000
Investors 1
| Date | Name | Website |
| 10.05.2022 | Water Stre... | waterstree... |
Mentions in press and media 9
| Date | Title | Description |
| 17.09.2024 | Pharmacovigilance in a Global Market: Key Compliance Strategies, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, gain insights into the current and future challenges of globalization in pharmacovigilance (PV). Attendees will learn about the PV regulatory inspection landscape, including key differences and commona... |
| 14.08.2024 | Advancing Precision Oncology: Radionuclide Conjugate and Antibody-Drug Conjugate (ADC) Development Strategies, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn about the current landscape of antibody-drug conjugates and radionuclide conjugates. Attendees will gain insights into regulatory constructs, submission readiness, dose structuring and optimizati... |
| 22.05.2024 | The Changing Paradigm of Regulatory Submissions: Embracing Automation, Gen AI, and Innovation for Faster Approvals, Upcoming Webinar Hosted by Xtalks | www.allucent.com In this free webinar, learn about the current landscape as well as the future of regulatory submissions, including the emerging trends in regulatory writing such as generative artificial intelligence (AI), automation and le... |
| 15.05.2024 | Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial | Allucent Will Conduct New Decentralized Phase IV Study Aimed at Counteracting Future Coronavirus Strains and Variants CARY, N.C., May 15, 2024 /PRNewswire/ -- Allucent, a global mid-sized clinical research organization (CRO), announced toda... |
| 14.11.2022 | Risk Assessment: Traditional and Novel Approaches to Assess and Manage Risks, Upcoming Webinar Hosted by Xtalks | Modeling approaches enable extrapolation of data from preclinical species to humans using established physiological differences. TORONTO (PRWEB) November 14, 2022 Risk assessment is a complex process intended to protect human health by iden... |
| 17.10.2022 | Benefits of Bayesian Dose Escalation Designs for Oncology Studies, Upcoming Webinar Hosted by Xtalks | These flexible methods may be more appropriate than those initially designed for chemotherapy drug development. TORONTO (PRWEB) October 17, 2022 As acceptance of flexible trial designs continues to advance, many sponsors are increasingly ex... |
| 26.08.2022 | No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak | Alex Nichols → When Mythic Therapeutics CEO Alex Nichols spoke to Endpoints News last December about the biotech’s $103 million Series B, he and fellow co-founder Brian Fiske emphasized safety, saying that they’re “really w... |
| 31.05.2022 | Inspection Readiness: What is it, why it matters, and what you need to know to be prepared, Upcoming Webinar Hosted by Xtalks | Good Clinical Practice (GCP) inspectors use different approaches depending on the regulatory authorities for which they represent; however, all of them will verify the compliance status on GCP and other applicable regulations during the ins... |
| - | Drug Development: Allucent Expands Use of Medidata Clinical Cloud | What You Should Know: – Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial o... |